Clinical Trials

Gallbladder Neoplasms, Cholangiocarcinoma

NCT06607185 2026-03-13

A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

GastrointestinalGynecologicThoracic

750 enrolled

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

NCT02336087 2026-02-04

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

21 enrolled

Pancreatic Adenocarcinoma

NCT06076837 2026-01-12

The Seven Trial: Exploiting the Unfolded Protein Response

6 enrolled

Pancreatic Cancer Metastatic

NCT02495896 2025-11-10

Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors

GastrointestinalHead & NeckThoracic

61 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Gallbladder Neoplasms, Pancreatic Neoplasms

NCT04615013 2025-10-30

NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

Phase 1 Recruiting

24 enrolled

GastrointestinalGynecologic

Cervical Esophagus Adenocarcinoma

NCT05497778 2025-10-14

A Phase 1b Study of Gemcitabine and Nab-paclitaxel in Combination With IM156 in Patients With Advanced Pancreatic Cancer.

19 enrolled

Pancreatic Neoplasms

NCT06182072 2025-10-01

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 1 Recruiting

46 enrolled

Pancreatic Ductal Adenocarcinoma (PDAC)

NCT03884556 2025-07-02

TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers

GastrointestinalGenitourinaryLymphoidThoracic

56 enrolled 19 charts

Urinary Bladder Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms

NCT03044613 2025-03-06

Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer

32 enrolled

Esophageal Neoplasms, Stomach Neoplasms

NCT04000906 2024-05-24

Nab-PIPAC

GastrointestinalGynecologic

18 enrolled

Carcinoma, Ovarian Epithelial, Pancreatic Neoplasms, Peritoneal Neoplasms

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT02231723 2023-11-18

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

139 enrolled

Pancreatic cancer, adult, Digestive System Neoplasms, Endocrine Gland Neoplasms, Adenoma, Islet Cell, Pancreatic Diseases, Pancreatic Neoplasms, Carcinoma, Islet Cell, Carcinoma, Pancreatic Ductal

NCT06017323 2023-10-25

ProglumidePanc

Phase 1 Withdrawn

Pancreatic Neoplasms

NCT02333188 2023-05-31

Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer

50 enrolled

Gallbladder Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma

NCT02930902 2023-02-09

Pembrolizumab and Paricalcitol With or Without Chemotherapy in Patients With Pancreatic Cancer That Can Be Removed by Surgery

9 enrolled

Resectable Pancreatic Carcinoma

NCT02227940 2022-07-25

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

38 enrolled

Pancreatic Neoplasms

NCT02608229 2021-04-21

BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

Phase 1 Terminated

18 enrolled 14 charts

Pancreatic Neoplasms

NCT02155088 2021-04-08

BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer

15 enrolled

Neoplasm Metastasis, Pancreatic Neoplasms, Recurrence

NCT03703063 2021-01-27

Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer

Phase 1 Unknown

30 enrolled

Pancreatic Neoplasms

NCT02389751 2019-07-24

Ganetespib in Combination With Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-III Esophageal Cancer

3 enrolled

Esophageal Neoplasms

NCT00732836 2016-02-05

Hepatic Arterial Infusion (HAI) of Abraxane

64 enrolled

Liver Neoplasms

NCT02048943 2015-01-09

Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer

Phase 1 Withdrawn

Pancreatic Neoplasms

NCT00028535 2013-06-04

Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

BreastGastrointestinalGynecologicThoracic

18 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Male, Small Cell Lung Carcinoma

NCT01161186 2012-10-11

Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma

15 enrolled